JSTL:BSEJeevan Scientific Technology Ltd Analysis
Data as of 2026-05-18 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Jeevan Scientific Technology Limited is trading at ₹81.74, comfortably above the 20‑day SMA (≈₹83.17) but below the 50‑day SMA (≈₹73.05), indicating a short‑term bullish bias. The RSI sits at 53, suggesting neutral momentum, while the MACD shows a bearish crossover (line ≈ 3.21 vs signal ≈ 3.94) and a negative histogram, warning of potential downside pressure. Price is near the identified support of ₹75.61 and well below the resistance of ₹93.90, with volume trending downward, which could limit upside momentum. Volatility is high at over 52% 30‑day and beta is very low (≈0.12), implying the stock moves sharply on its own rather than with the market. On the fundamentals side, revenue surged 52.5% YoY and gross margins are exceptional (~90%), yet the company posted a –3.7% profit margin, negative EPS (‑1.28) and carries a large debt load (≈₹249 M) with a debt‑to‑equity of 52.8, making earnings sustainability a concern. The price‑to‑book of 2.72 and price‑to‑sales of 3.24 suggest the market is pricing in growth expectations despite the lack of profitability, while the Fear‑Greed Index at 87.16 signals extreme greed in the broader market.
Market Outlook
Short Term
< 1 yearKey Factors
- Price hovering just above key support at ₹75.61
- Bearish MACD crossover and negative histogram
- Decreasing volume and high short‑term volatility
Medium Term
1–3 yearsKey Factors
- Strong revenue growth (52.5% YoY) and high gross margins
- Continued net losses and elevated debt‑to‑equity ratio
- Neutral momentum indicators (RSI ~53, bullish trend direction)
Long Term
> 3 yearsKey Factors
- Expanding biotech services market in India
- Robust top‑line growth and potential to improve profitability
- Current valuation reflects growth expectations despite earnings gaps
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.